Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 of a 4-Part Series
Featuring perspectives from Dr Kathleen N Moore, including the following topics: Introduction: SOLO-1 Trial (0:00) Case: A woman in her mid 50s with a germline BRCA1 mutation who received IV/IP chemotherapy followed by olaparib maintenance experiences disease recurrence — Neil Morganstein, MD (15:58) Case: A woman in her late 50s with a germline BRCA2 mutation undergoes surgery and chemotherapy for Stage II high-grade serous ovarian cancer (HGSOC) — Kellie E Schneider, MD (24:38) Case: A woman in her late 70s with a somatic BRCA2 mutation and Stage IVB HGSOC who experienced disease progression on the placebo arm of the PRIMA trial and recurrence in 2019 receives liposomal doxorubicin/carboplatin and maintenance niraparib — Karim ElSahwi, MD (30:37) Case: A woman in her early 50s presents with recurrent BRCA wild-type (WT), homologous recombination deficiency (HRD)-negative clear cell ovarian cancer after interval debulking surgery — Dana M Chase, MD (35:16) Case: A woman in her early 60s with BRCA WT, HRD-negative, folate receptor alpha-positive ovarian cancer experiences primary disease progression on neoadjuvant carboplatin/paclitaxel and receives mirvetuximab soravtansine — Priya Rudolph, MD, PhD (46:49) Investigator Survey (58:37) CME information and select publications